Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 3/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CAT | P04040 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17896570 | 0.85 | GLRA3 (0.44) | DAOARDHODHCES2CAT | |
| SCHEMBL19585735 | 0.82 | DAO (0.42) | KIF11DAOKMOARALDH1A1 | |
| SCHEMBL936925 | 0.81 | DAO (0.46) | KIF11DAOKMOARALDH1A1 | |
| SCHEMBL22207733 | 0.80 | SCN10A (0.39) | TAS2R14NOTUM | |
| SCHEMBL27379121 | 0.80 | TAS2R14 (0.41) | TAS2R14DAOKMODHODHHDAC6 | |
| SCHEMBL30755336 | 0.80 | TAS2R14 (0.41) | TAS2R14DAOKMODHODHHDAC6 | |
| SCHEMBL6302351 | 0.80 | FABP3 (0.44) | DAOALDH1A1NOTUMCES2CAT | |
| SCHEMBL30673290 | 0.80 | FABP3 (0.44) | DAOALDH1A1NOTUMCES2CAT | |
| SCHEMBL31459345 | 0.78 | ALDH1A1 (0.49) | HDAC6ALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL22207903 | 0.78 | TAS2R14 (0.42) | TAS2R14KIF11DAOKMOAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441703-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| US-20230062053-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-03-02 | — | — | US | disclosed |
| US-20230062053-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-03-02 | — | — | US | disclosed |
| WO-2022224223-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| WO-2020146682-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146682-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441703-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | TAS2R14 297/4885KIF11 4446/4885DAO 3224/4885 |
| US-20230062053-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | TAS2R14 297/4885KIF11 4446/4885DAO 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.